Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Taselisib is a potent and selective tumor growth inhibitor through PI3K pathway suppression. Thirty-four patients with locally advanced or metastatic solid tumors were treated (phase I study, modified 3+3 dose escalation; 5 cohorts; 3-16 mg taselisib once daily capsule). Taselisib pharmacokinetics w...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Discov
Hoofdauteurs: Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K., Wilson, Timothy R., Ware, Joseph A., Sanabria Bohorquez, Sandra M., Savage, Heidi M., Sampath, Deepak, Salphati, Laurent, Lin, Ray S., Jin, Huan, Parmar, Hema, Hsu, Jerry Y., Von Hoff, Daniel D., Baselga, Jose
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5501742/
https://ncbi.nlm.nih.gov/pubmed/28331003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1080
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items